Top Ten most popular articles on Pharmafile.com this week
pharmafile | November 30, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten
We’ve come to the end of November, and with only one month of the year left to go, the industry is still pushing forward with regular new drug approvals. A number of these made our top ten most popular stories this week, but the most read story on Pharmafile.com was the news that Immuno Biotech owner David Noakes will be sentenced for offering an unlicensed and untested “cure” for HIV, cancer and autism.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Roche’s Genentech to acquire inflammatory drug discovery firm Jecure
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions, in a bid to square up to rivals in the treatment of fatty liver disease.
9. NHS hospitals paying 167% more for drugs since 2010/11
Medicines are costing the NHS more than 50% more than a decade ago, while hospitals are paying more than twice as much for their drugs since 2010/11, according to new figures published by NHS Digital.
8. Sun Pharma’s New Jersey manufacturing overhaul puts 96 jobs at risk
Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.
7. Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
Novartis’ one-time gene therapy Luxturna has been awarded approval by the European Commission for the treatment of vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells.
6. Probiotics have no effect on children with gastroenteritis, study shows
Despite the claims of marketing campaigns and advertisements, probiotics have no effect on gastroenteritis on children, according to a new study from the University of Calgary.
5. Mundipharma’s Neulasta biosimilar approved in EU
Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European Commission.
4. European Commission approves first and only long-acting opioid dependence therapy
Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) confirms the marketing authorisation of Camurus’ Buvidal (CAM2038).
3. Mundipharma name GSK veteran as new Senior Vice President & CFO
The Mundipharma network has confirmed the appointment of Arnaud Breabout, to the position of Senior Vice President & Chief Financial Officer.
2. NHS to save £300 million by switching to Humira biosimilars
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of AbbVie’s best-selling anti-inflammatory drug Humira (adalimumab), bringing the current annual total spent on the drug down by 75%.
The owner of Guernsey-based biotech Immuno Biotech Ltd, David Noakes, will be sentenced this week after admitting to a number of charges concerning the sale of unproven and unlicensed HIV, cancer and autism ‘cure’ GcMAF.
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
